No Data
No Data
Express News | Obi Pharma Announces Phase 1/2 Study Initiation for Obi-992, a Trop2-Targeted Antibody-Drug Conjugate (ADC) for Cancer Therapy
Tropicana Widens Loss in Q1
Tropicana Corp. (KLSE:TROP) incurred a loss attributable to owners of 9.1 million ringgit in the first quarter, higher than 5.2 million ringgit a year earlier. Diluted loss per share rose to 0.003 rin
Express News | Biohaven Announces First Patient Dosed in Phase 1/2 Study of BHV-1510, a Trop-2 Directed Antibody Drug Conjugate
Biohaven Doses First Patient With Its Novel Trop-2 Directed Antibody Drug Conjugate (ADC) BHV-1510 in Advanced or Metastatic Epithelial Tumors
Biohaven Ltd. (NYSE: BHVN) (Biohaven), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization...
Meaningful Improvement in Overall Survival (OS) and Tolerability Observed in Patients Receiving Trilaciclib in Combination With a TROP2 Antibody-Drug Conjugate (ADC)
- New Positive Phase 2 Results in Metastatic Triple Negative Breast Cancer (mTNBC) Indicate That Use of Trilaciclib in Combination with a TROP2 ADC May Be Associated with Improved Median OS Compared to Historical Data
Corning Jerry completes first patient administration in phase I clinical study of HER3/TROP2 dual antibody ADC drug JSKN016
SUZHOU, May 22, 2024/PRNewswire/ -- Corning Jerry Biopharmaceuticals (stock code: 9966.HK) announced that the Phase I clinical study (study number: JSKN016-101) of the HER3/TROP2 dual-antibody ADC drug JSKN016 in patients with advanced malignant solid tumors in China has completed its first patient administration. TROP2 (Trophoblast cell surface antigen 2, human trophoblast cell surface antigen 2) is widely expressed in solid tumors, and its upregulation can promote tumor growth
No Data